Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
Background: Primary effusion lymphoma (PEL), plasmablastic lymphoma (PBL), and Multicentric Castleman Disease (MCD) are aggressive forms of cancer that affects cells in the immune system and lymph nodes. How they develop is not well understood, and these diseases do not respond well to standard treatments for other types of lymphomas. Objective: To test a drug treatment (daratumumab SC) in people with PEL, PBL, or MCD. Eligibility: People aged 18 and older with PEL, PBL, or MCD who must have failed to respond to therapy or they must be unable to receive standard treatment for the disease. Design: Participants will be screened. They will have a physical exam with blood tests. They will have imaging scans and tests of their heart and lung function. They may need to have a biopsy: tissue or fluid will be collected. They will have an eye exam. Daratumumab SC is given as an injection into the fat under the skin in the abdomen. This takes 3 to 5 minutes. Participants will receive the treatment once a week for 8 weeks; then every 2 weeks for 16 weeks; then every 4 weeks for up to 24 months. Participants will have other tests during the study period. These may include lumbar punctures: A needle will be inserted between the bones of the spine to draw some fluid from the area around the spinal cord. Participants may also have a thoracentesis: A needle or plastic tube will be inserted into the space around the lungs to withdraw fluid. Participants will have more imaging scans and blood tests. Follow-up visits will continue after treatment ends. Participants will be in the study for up to 5 years.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Masz potwierdzony jeden z następujących nowotworów: chłoniak pierwotny wysiękowy (PEL), chłoniak plazmablastyczny (PBL) lub wieloogniskowa choroba Castlemana (MCD).
- •Twój nowotwór nawrócił lub nie zareagował na dotychczasowe leczenie chemioterapią, albo nie możesz otrzymać standardowej chemioterapii.
- •Masz ukończone 18 lat.
- •Twój stan ogólny pozwala na uczestnictwo w badaniu (w skali ECOG 0-2 lub 3, jeśli wynika z choroby).
- •Twoje podstawowe funkcje organizmu, takie jak poziom hemoglobiny (powyżej 7 g/dL) i działanie nerek (filtrowanie powyżej 15 ml/min), są wystarczające.
- •Jeśli chorujesz na chłoniaka pierwotnego wysiękowego lub plazmablastycznego, musiałeś otrzymać standardowe leczenie chemioterapią (zawierające antracykliny) lub istnieją przeciwwskazania do jego zastosowania.
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Maximum age
- 120 Years
- Last updated (source)
- July 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
National Institutes of Health Clinical Center
Bethesda, United States
Trial contact
Anaida Widell
Robert Yarchoan, M.D.
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.